Clinical Trial Update: Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating zanidatamab in combination with pembrolizumab and chemotherapy as first-line therapy for metastatic gastroesophageal adenocarc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Adenocarcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Zanidatamab

Snippet

Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Conditions: Gastroesophageal Adenocarcinoma, First Line Therapy | Phase 2 | Status: RECRUITING